



Publication : The Economic Times
Date : December 02, 2014
Page : 06
Title : Ranbaxy launches
Bio-similar Arthritis Drug

In a Nutshell

■ Ranbaxy Launches Bio-similar Arthritis Drug

NEW DELHI Ranbaxy Laboratories launched the first bio-similar version of Johnson and Johnson's Remicade, a drug used for treating various conditions, including rheumatoid arthritis. Infimab has been introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, Ranbaxy said in a statement. Infimab will be manufactured by Reliance Life Sciences at its facility in Mumbai, it added. Remicade is currently marketed for the treatment of inflammatory diseases, including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis.